Single-tablet regimens – a new era of antiretroviral therapy

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

When prescribing an antiretroviral therapy (ART) regimen, preference is given to fixed combinations of drugs, especially drugs in which the entire ART regimen is presented in one tablet, which is an advantage due to the reduction in the number of tablets, the frequency of drug administration and the guaranteed adherence to prescribed doses and drug combinations.

The review presents data on the efficacy, safety and tolerability of drugs registered in Russia, Biktarvy, Delstrigo, Elpida® Combi and Dovato. They include combinations of active substances of the latest generations, which differ from previously used ones by better tolerability and safety, a high barrier of resistance and a narrower spectrum of drug-drug interactions, which allows them to be used even in patients with combined pathology and in elderly patients. Currently, these drugs are included in the preferred regimens for the initiation of ART in most patients with HIV infection in domestic and foreign recommendations.

Full Text

Restricted Access

About the authors

Veronika G. Kanestri

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Author for correspondence.
Email: kanestri@yandex.ru
ORCID iD: 0000-0002-2234-7094

MD, Senior Researcher

Russian Federation, Moscow

Alexey V. Kravchenko

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: alexey-kravtchenko@yandex.ru
ORCID iD: 0000-0001-7857-3763

Professor, MD, Leading Researcher

Russian Federation, Moscow

Oleg G. Yurin

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being

Email: oleg_gerald@mail.ru
ORCID iD: 0000-0002-9290-9048

MD, Leading Researcher, Central Research Institute of Epidemiology

Russian Federation, Moscow

References

  1. Bhatti A.B., Usman M., Kandi V. Current scenario of HIV/AIDS, treatment options, and major challenges with compliance to antiretroviral therapy. Cureus 2016; 8(3): e515. doi: 10.7759/cureus.515
  2. Collins S.E., Grant P.M., Shafer R.W. Modifying antiretroviral therapy in virologically suppressed HIV-1-infected patients. Drugs 2016; 76(1): 75–98. doi: 10.1007/s40265-015-0515-6
  3. Kangethe A., Polson M., Lord T.C., Themmi E., Oglesby A. Real-world healthplan data analysis: key trends in medication adherence and overall costs in patients with HIV. J. Manag. CareSpec. Pharm. 2019; 25(1): 88–93. doi: 10.18553/jmcp.2019.25.1.088
  4. De Miguel Buckley R., Montejano R., Stella-Ascariz N., Jose R.A. New strategies of ARV: the road to simplification. Curr. HIV/AIDS Rep. 2018; 15: 11–19. doi: 10.1007/s11904-018-0371-6
  5. Kapadia S.N., Grant R.R., German S.B., Singh B., Davidow A.L., Swaminathan S. et al. HIV virologic response better with single-tablet once daily regimens compared to multiple-tablet daily regimens. SAGE Open Med. 2018; (6): 1–8. doi: 10.1177/2050312118816919
  6. Hemmige V., Flash C.A., Carter J., Giordano T.P., Zerai T. Single tablet HIV regimens facilitate virologic suppression and retention in care among treatment naive patients. Aids Care 2018; 30(8): 1017–1024. doi: 10.1080/09540121.2018.1442554
  7. Clay P.G., Yuet W.C., Moecklinghoff C.H., Duchesne .I., Tronczynski K.L., Shah S. et al. A meta-analysis comparing 48-week treatment outcomes of single and multi-tablet antiretroviral regimens for the treatment of people living with HIV. Aids Res. Ther. 2018; 15(1): 17–27. doi: 10.1186/s12981-018-0204-0
  8. Mondi A., Lorenzini P., Tavelli A., Cozzi-Lepri A., Maggiolo F., Gianotti N. et al. Effectiveness of single vs multiple tablet regimens as first-line art in icona cohort. CROI 2019. Abstr. 0511.
  9. Altice F., Evuarherhe O., Shina S., Carter G., Beaubrun A.C. Adherence to HIV treatment regimens: systematic literature review and meta-analysis. Patient Prefer. Adherence 2019; 13: 475–490. doi: 10.2147/PPA.S192735
  10. Furtado Dos Santos S., Almeida-Brasil C.C., Costa J.O., Reis E.A., Afonso Cruz M., Silveira M.R. et al. Does switching from multiple to single-tablet regimen containing the same antiretroviral drugs improve adherence? A group-based trajectory modeling analysis. Aids Care 2020; 32(1): 1268–1276. doi: 10.1080/09540121.2020.1736258
  11. Colombo G.L., Di Matteo S., Maggiolo F. Antiretroviral therapy in HIV-infected patients: a proposal to assess the economic value of the single-tablet regimen. Clinicoecon. Outcomes Res. 2013; 5: 59–68. doi: 10.2147/CEOR. S38977
  12. Sweet D.E., Altice F.L., Cohen C.J., Vandewalle B. Cost-Effectiveness of Single- Versus Generic Multiple-Tablet Regimens for Treatment of HIV-1 Infection in the United States. PloS One 2016; 11(1): e0147821. doi: 10.1371/journal.pone.0147821
  13. Покровский В.В., Юрин О.Г., Кравченко А.В., Беляева В.В., Ермак Т.Н., Шахгильдян В.И. и др. Рекомендации по лечению ВИЧ-инфекции и связанных с ней заболеваний, химиопрофилактике заражения ВИЧ. Национальная ассоциация специалистов по инфекционным болезням имени академика В.И. Покровского. Эпидемиол. инфекц. болезни. Актуал. вопр. 2024; 14(4, приложение), 108 с. Pokrovsky V.V., Yurin O.G., Kravchenko A.V., Belyaeva V.V., Ermak T.N., Shakhgildyan V.I. et al. [Recommendations for the treatment of HIV infection and related diseases, chemoprophylaxis of HIV infection]. Epidemiоlоgy and infectious diseases. Сurrent items 2014; 14(4, appendix), 108 p. (In Russ.).
  14. Anstett K., Brenner B., Mesplede T., Wainberg M.A. HIV drug resistance against strand transfer integrase inhibitors. Retrovirology 2017; 14(1): 36. doi: 10.1186/s12977-017-0360-7
  15. Daar E., de Jesus E., Ruane P., Crofoot G., Oguchi G., Creticos C. et al. Phase 3 randomized, controlled trial of switching to fixed-dose bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) from boosted protease inhibitor-based regimens in virologically suppressed adults: week 48 results. Open Forum Infectious Diseases 2017; 4(1): S735. doi: 10.1093/ofid/ofx180.003
  16. Molina J.M., Ward D., Brar I., Mills A., Stellbrink H.J., Lopez-Cortes L. et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV 2018; 5(7): 357–365. doi: 10.1016/S2352-3018(18)30092-4
  17. Kityo C., Hagins D., Koenig E., Avihingsanon A., Chetchotisakd P., Supparatpinyo K. et al. Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial. Acquir. Immune Defic. Syndr. 2019; 82(3): 321–328. doi: 10.1097/QAI.0000000000002137
  18. Maggiolo F., Rizzardini G., Molina J., Pulido F., de Wit S., Vandekerckhove L. et al. Switching to bictegravir/emtricitabine/tenofovir alafenamide in adults aged >65 years or older: Week 72 results from an international, phase IIIb, open-label trial. HIV Drug. Therapy 2020. Abstr. P038
  19. Orkin C., Squires K.E., Molina J.M., Sax P.E., Sussmann O., Lin G. et al. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial. Clin. Infect. Dis. 2021; 73(1): 33–42. doi: 10.1093/cid/ciaa822
  20. Kumar P., Johnson M., Molina J., Rizzardini G., Cahn P., Bickel M. et al. Long-term treatment efficacy and safety following switch to doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF): Week 144 results of the DRIVE-SHIFT trial. HIV Drug Therapy 2020; Abstr. P037
  21. Khalilieh S., Yee K.L., Liu R., Fan L., Sanchez R.I., Auger P. et al. Moderate Hepatic Impairment Does Not Affect Doravirine Pharmacokinetics. J. Clin. Pharmacol. 2017; 57(6): 777–783. doi: 10.1002/jcph.857
  22. Кравченко А.В., Орлова-Морозова Е.А., Шимонова Т.Е., Козырев О.А., Нагимова Ф.И., Захарова Н.Г. и др. Эффективность и безопасность нового российского ненуклеозидного ингибитора обратной транскриптазы элсульфавирина в сочетании с тенофовиром/эмтрицитабином – многоцентровое сравнительное исследование с эфавирензом у пациентов с ВИЧ-инфекцией, ранее не получавших лечения. Инфекционные болезни 2017; 15(3): 5–13. doi: 10.20953/1729-9225-2017-3-5-13. Kravchenko A.V., Orlova-Morozova E.A., Shimonova T.E., Kozyrev O.A., Nagimova F.I., Zakharova N.G. et al. [Efficacy and safety of the new Russian non-nucleoside reverse transcriptase inhibitor elsulfavirine in combination with tenofovir/emtricitabine - a multicenter comparative study with efavirenz in patients with HIV infection who have not previously received treatment]. Infectious diseases 2017; 15(3): 5–13. (In Russ.). doi: 10.20953/1729-9225-2017-3-5-13
  23. Кравченко А.В., Шимонова Т.Е., Ульянова Я.С., Кузнецова А.В., Исаева Г.Н., Сизова Н.В. и др. Результаты пострегистрационного исследования эффективности и безопасности схем антиретровирусной терапии, включающей элсульфавирин, у пациентов с ВИЧ-инфекцией, ранее не получавших лечения (ПРИБ-1). Эпидемиол. инфекц. болезни. Актуал. вопр. 2024; 14(3): 89–100. doi: 10.18565/epidem.2024.14.3.89-100. Kravchenko A.V., Shimonova I.E., Ulyanova Y.S., Kuznetsova A.V., Isaeva G.N., Sizova N.V. et al. [Results of post-registration study of efficacy and safety of antiretroviral therapy schemes including elsulfavirine in previously non-treated HIV-infected patients (PASS-1)]. Epidemiоlоgy and infectious diseases. Сurrent items 2024; 14(3): 89–100. (In Russ.). doi: 10.18565/epidem. 2024.14.3.89-100
  24. Открытое рандомизированное в параллельных группах клиническое исследование HIV-VM1500FDC-02 сравнительной фармакокинетики и биоэквивалентности препарата VM-1500FDC (АО «ИИХР», Россия) и препаратов Элпида® (ООО «Вириом», Россия), Виреад® (Гилеад Сайенсиз Айелэнд Юси, Великобритания) и Эмтрицитабин® (ЗАО «БИОКАД», Россия) при их совместном приеме однократно натощак у здоровых добровольцев. https://grlsbase.ru/clinicaltrails/clintrail/27. [An open-label, randomized, parallel-group clinical study HIV-VM1500FDC-02 of comparative pharmacokinetics and bioequivalence of VM-1500FDC (JSC IIHR, Russia) and Elpida® (OOO Viriom, Russia), Viread® (Gilead Sciences Ireland US, UK) and Emtricitabine® (ZAO BIOCAD, Russia) when administered together once on an empty stomach in healthy volunteers]. (In Russ.). https://grlsbase.ru/clinicaltrails/clintrail/27
  25. Cahn P., Madero J.S., Arribas J.R,, Antinori A., Ortiz R., Clarke A.E. et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet 2019; 393(10167): 143–155. doi: 10.1016/S0140-6736(18)32462-0
  26. Cahn P., Madero J.S., Arribas J.R., Antinori A., Ortiz R., Clarke A.E. et al. Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-naïve adults with hiv-1 infection – 3-year results from the Gemini studies. HIV Drug Therapy. 2020. Abstr. P018
  27. De Wit S., Bonnet F., Osiyemi O., Bisshop F., Olalla J., Routy J.P. Durable efficacy of switching from a 3- or 4-drug tenofovir alafenamide–based regimen to the 2-drug regimen dolutegravir/lamivudine in the TANGO study through week 196. J. Acquir. Immune Defic. Syndr. 2024; 96(2): 156–160. doi: 10.1097/QAI.0000000000003395
  28. Llibre J.M., Brites C., Cheng C.Y., Osiyemi O., Galera C., Hocqueloux L. et al. Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial. Clin. Infect. Dis. 2023; 76(4): 720–729. doi: 10.1093/cid/ciac130
  29. Канестри В.Г., Кравченко А.В., Покровская А.В., Кулабухова Е.И., Куимова У.А., Голиусова М.Д. и др. Рандомизированное открытое контролируемое сравнительное исследование по переключению больных ВИЧ-инфекцией с опытом антиретровирусной терапии на схему, включавшую DTG И 3ТС: результаты 96 недель. Эпидемиол. инфекц. болезни. Актуал. вопр. 2021; 11(4): 45–52. doi: 10.18565/epidem.2021.11.4.45-52. Kanestri V.G., Kravchenko A.V., Pokrovskaya A.V., Kulabukhova E.I., Kuimova U.A., Goliusova M.D. et al. [Randomized, open-label, controlled, comparative study on switching HIV-infected patients with their antiretroviral therapy experience to a DTG and 3TC regimen: 96-weeks results]. Epidemiоlоgy and infectious diseases. Сurrent items 2021; 11(4): 45–52. (In Russ.). doi: 10.18565/epidem.2021.11.4.45-52
  30. Канестри В.Г. Шахгильдян В.И., Покровская А.В., Коннов Д.С., Кулабухова Е.И., Козырина Н.В. и др. Антиретровирусная терапия и изменение веса в реальной клинической практике. Материалы IX Санкт-Петербургского форума по ВИЧ-инфекции с международным участием, посвященного 35-летию Санкт-Петербургского Центра по профилактике и борьбе со СПИД и инфекционными заболеваниями. СПб., 2024; 18–25. Kanestri V.G., Shakhgildyan V.I., Pokrovskaya A.V., Konnov D.S., Kulabukhova E.I., Kozyrina N.V. et al. [Antiretroviral therapy and weight change in real clinical practice. IX St. Petersburg forum on HIV Infection with international participation, dedicated to the 35th anniversary of the St. Petersburg Center for the Prevention and Control of AIDS and Infectious Diseases]. St. Petersburg, 2024; 18–25. (In Russ.).

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Bionika Media